Clinical Trials · NCT01496131
Tecemotide (L-BLP25) in Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- EMD Serono
- Enrollment
- 28
- Start date
- Oct 2011
- Locations
- 1 site, United States
- Primary endpoint
- Number of Subjects With Change From Baseline in the Mucinous Glycoprotein 1 (MUC1) Specific Systemic T-Cells Immune Response at Day 60 (Pre-Radiation)